Real-world evidence of the effect of adjunctive semaglutide on weight change, glycemic control, and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes
Source
Diabetes technology and therapeutics - ISSN 1520-9156- (2025) p.
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration
Source
Clinical epigenetics - ISSN 1868-7075-17:1 (2025) p. 1-22
Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
Source
Cardiovascular diabetology - ISSN 1475-2840-24:1 (2025) p. 1-11
Reply to: "Correspondence on "Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD""
Source
Journal of hepatology - ISSN 0168-8278-83:1 (2025) p. e21-e22
Global research initiative for patient screening on MASH (GRIPonMASH) protocol : rationale and design of a prospective multicentre study
Source
BMJ open - ISSN 2044-6055-15:5 (2025) p. 1-11